ストックスクリーナーアプリを入手
0.5429
3.05%
-0.0171
アフターアワーズ：
.56
0.0171
+3.15%
Mustang Bio Inc (MBIO) 最新ニュース
Mustang Bio Stock Price Forecast. Should You Buy MBIO? - StockInvest.us
Mustang Bio Inc. (MBIO) Key Financial Ratios – Valuation, Profitability & More - Value Research
Mustang (MBIO) EPS and Revenue: EPS Misses Its Estimate in the Latest Session; Market Response: The Market Price Moves 0.70% Higher in the Latest ReadingManagement Tone Analysis - vinanet.vn
Pediatrix (MD) Trading-Day Recap: Ends Higher by 0.84% at $26.56 on the Day; Level Position: Support at $25.23 and Resistance at $27.89 Frame the RangeReversal Trade - vinanet.vn
BHE Q2 2026 Earnings: EPS Beats Estimates by 8.4% as Bottom-Line Strength Drives Shares HigherROIC Trend Report - Vinanet
Mustang Bio (MBIO) Edges Higher by 3% as Shares Test Key Resistance at $0.64Dark Pool Prints - Vinanet
Mustang Bio Inc. (MBIO) Holds Steady at $0.60 as Narrow Trading Range PersistsFundamentals - dars.gov.et
Mustang Bio Inc (MBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Segment Evaluation and Major Growth Areas in the Viral Vector Production (Research-Use) Market - openPR.com
Leading Companies Consolidating Their Presence in the Viral Vector Manufacturing Market - openPR.com
Mustang Bio Q2 net loss widens 41% to $1.07 million - Bitget
MUSTANG BIO, INC. Q2 2026: Net income $(1.07)M, EPS $(0.16) — 10-Q Summary - TradingView
MBIO: Net loss widened, cash reserves declined, and Nasdaq delisting risk remains amid ongoing R&D focus - TradingView
Mustang Bio, Inc. (NASDAQ: MBIO) posts $2.0M loss and faces Nasdaq bid-price warning - Stock Titan
Mustang Bio (MBIO) Holds $0.58 Support Zone as Gene Therapy Stock Ticks HigherPCR Moving Average - dars.gov.et
Fortress Biotech Just Netted $159 MillionIts Preferred Shares Could Be The Real Winner - Seeking Alpha
Glioblastoma Pipeline 2026: FDA Approvals, Therapies, - openPR.com
Mustang Bio Inc (MBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mustang Bio, Inc. Revenue Breakdown – NASDAQ:MBIO - TradingView
Mustang Bio Inc (MBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mustang Bio Inc (MBIO) Cash Flow - TradingKey
MBIO|Mustang Bio Inc|Price:0.560|Chg%:-0.002 - TradingKey
TradingKey - TradingKey
MBIO Q4 2024 Earnings: Deep EPS Miss Highlights Challenges for Clinical-Stage BiotechTrough Earnings Signal - vinanet.vn
Europe Gene Therapy Market Size, Growth & Forecast, 2034 - Market Data Forecast
Frontier tech research, news & data - MLQ.ai
Mustang Containment Solutions Acquires Mustang Extreme's Western and Southwestern Environmental Lining and Water Management Assets - Yahoo Finance
MBIO Q4 2024 Earnings: Significant EPS Miss Amid Pre-Revenue Biotech OperationsCore Business Growth - vinanet.vn
Car T Cell Therapy Market Set to Booming Growth 2026-2033 | Novartis AG, Gilead Sciences, Inc - EIN News
Mustang Bio stock trades lower as cash runway and trial update shape outlook - Ad-hoc-news.de
Mesa Royalty Trust (MTR) Declines 2.2% as Stock Nears Critical Support at $2.95Shakeout Pattern - po-news-eg.net
MSN Money - MSN
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Significant EPS Miss Amidst Ongoing Operational ChallengesAnalyst Drop Coverage - dars.gov.et
Americore Resources Appoints Justin Hanka to Its Board of Directors - Moomoo
MBIO Q4 2024 Earnings: EPS Misses Estimates by Wide Margin Amid Operational ChallengesDiluted EPS Report - vinanet.vn
AstraZeneca’s Clinical Setback Casts Doubt on Premium Valuation Amid Pipeline ConcernsMargin Expansion Trends - po-news-eg.net
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Deep Losses Overshadow Progress in CAR T PipelineGuidance Update - DonanımHaber
Mustang Bio (MBIO) Q1 2026 earnings summary - Quartr
Mustang Bio (MBIO) Proxy Filing Summary - Quartr
Mustang Bio (MBIO) Registration Filing Summary - Quartr
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Significant EPS Miss Reflects Operational ChallengesStrong Earnings Momentum - po-news-eg.net
TDW Q1 2026 Earnings: Significant EPS Miss Despite Stock GainDebt Analysis Report - dars.gov.et
MBIO Should I Buy - Intellectia AI
MBIO Q4 2024 Earnings: Massive EPS Miss as Clinical-Stage Biotech Reports No RevenueEarnings Revision Report - dars.gov.et
MBIO Q4 2024 Earnings: Significant EPS Miss as Pre-Revenue Biotech Continues DevelopmentFinancial Summary - dars.gov.et
Enterprise value to EBIT forward of Mustang Bio, Inc. – NASDAQ:MBIO - TradingView
Enterprise value to EBITDA forward of Mustang Bio, Inc. – NASDAQ:MBIO - TradingView
Enterprise value to EBIT forward of Mustang Bio, Inc. – BOATS:MBIO - TradingView
Price to earnings forward of Mustang Bio, Inc. – NASDAQ:MBIO - TradingView
Price to book forward of Mustang Bio, Inc. – NASDAQ:MBIO - TradingView
Price to earnings forward of Mustang Bio, Inc. – BOATS:MBIO - TradingView
Enterprise value to revenue forward of Mustang Bio, Inc. – NASDAQ:MBIO - TradingView
Price to sales forward of Mustang Bio, Inc. – NASDAQ:MBIO - TradingView
Price to sales forward of Mustang Bio, Inc. – BOATS:MBIO - TradingView
Traders are paying attention to the gapping stocks in Friday's session. - ChartMill
Mustang Bio Inc (MBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Mustang Bio, Inc. Actuals & Estimates (NASDAQ:MBIO) - TradingView
MBIO Q4 2024 Earnings: Massive EPS Miss as Pre-Revenue Biotech Faces Cash Burn ChallengesGAAP Earnings Report - Bölüm Sonu Canavarı
Silver Tiger Metals Inc.'s (TSE:SLVR) Path To Profitability - simplywall.st
Mustang Bio Inc. (MBIO) Edges Higher Amid Tight Trading Range: Key Levels in FocusAAII Bullish - dars.gov.et
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Significant EPS Miss Reflects Ongoing Clinical-Stage Challenges - dars.gov.et
MBIO Q4 2024 Earnings: Wider-than-Expected Loss Amid Clinical ProgressGuidance Revision Trend - dars.gov.et
Glioma Pipeline Insights Accelerates as 180+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):